The efficacy of post-cardiopulmonary bypass dosing of vancomycin in cardiac surgery

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 14, Issue 4, 2010, Pages 301-304

  Raikhelkar, Jayashree K ^a   Reich, David L ^a   Schure, Rebecca ^b   Varghese, Robin ^a   Bodian, Carol ^a   Scurlock, Corey ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

antibiotic prophylaxis; cardiopulmonary bypass; vancomycin levels

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ANESTHESIA INDUCTION; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEALTH CENTER; HEART SURGERY; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE UNIT; MALE; OPERATING ROOM; POSTOPERATIVE PERIOD; SURGICAL INFECTION;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CARDIOPULMONARY BYPASS; COHORT STUDIES; CORONARY CARE UNITS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PATIENT READMISSION; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; SURGICAL WOUND INFECTION; VANCOMYCIN;

EID: 78650821119     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253210383337     Document Type: Article

References (13)

1. Culliford AT, Cunningham Jr JN, Zeff RH, Isom OW, Teiko P., Spencer FC Sternal and costochondral infections following open-heart surgery: a review of 2,594 cases. J Thorac Cardiovasc Surg. 1976 ; 72: 714-726.
2. Engermann JJ, Carmeli Y., Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003 ; 36: 592-598.
3. Rosenthal MB Nonpayment for performance? Medicare's new reimbursement rule. N Engl J Med. 2007 ; 357: 1573.
4. Moran GJ, Krishnadasan A., Gorwitz RJ, et al. EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006 ; 355: 666-674.
5. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Disease Pharmacists. Clin Infect Dis. 2009 ; 49: 325-327.
6. Wiedemann B., Atkinson BA Susceptibility to antibiotics: species incidence and treads. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Baltimore, MD: Williams and Wilkins; 1991: 962-1208.
7. Engelman R., Shahian D., Shemin R., et al. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part ii: antibiotic choice. Ann Thorac Surg. 2007 ; 83: 1569-1576.
8. Movahed M., Kasravi B., Bryan CS Prophylactic use of vancomycin in adult cardiology and cardiac surgery. J Cardiovasc Pharmacol Ther. 2004 ; 9: 13-20.
9. Vuorisalo S., Pokela R., Syrjala H. Is single-dose antibiotic prophylaxis sufficient for coronary artery bypass surgery? An analysis of peri- and postoperative serum cefuroxime and vancomycin levels. J Hosp Infect. 1997 ; 37: 237-247.
10. Garcia MP, Marti-Bonmati E., Serrano JG, et al. Alterations of vancomycin pharmacokinetics during cardiopulmonary bypass in patients undergoing cardiac surgery. Am J Health Syst Pharm. 2003 ; 60: 260-265.
11. Farber BF, Karchmer AW, Buckley MJ, et al. Vancomycin prophylaxis in cardiac operations: determination of an optimal dosage regimen. J Thorac Cardiovasc Surg. 1983: 85: 933-940.
12. Kitzes-Cohen R., Farin D., Piva G., et al. Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery. Ther Drug Monit. 2000 ; 22: 661-667.
13. Miglioli PA, Merlo F., Grabocka E., et al. Effects of cardiopulmonary bypass on vancomycin plasma concentrations decay. Pharmacol Res. 1998 ; 38: 275-278.